We are international
Donate
• videos TEXT SIZE   
webcasts from medical meetings    back

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.
06.10.07
Jean Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France


 related articles